Earticle

현재 위치 Home

Original Article

L-asparaginase 약물 유해 반응 보고 분석
Analysis of L-asparaginase Related Adverse Reaction

첫 페이지 보기
  • 발행기관
    한국임상약학회 바로가기
  • 간행물
    한국임상약학회지 KCI 등재 바로가기
  • 통권
    제27권 제3호 (2017.09)바로가기
  • 페이지
    pp.143-149
  • 저자
    고경미, 나현오
  • 언어
    한국어(KOR)
  • URL
    https://www.earticle.net/Article/A310749

※ 기관로그인 시 무료 이용이 가능합니다.

4,000원

원문정보

초록

영어
Background: L-asparaginase (L-ASP) is a critical agent for the treatment of acute lymphoblastic leukemia and lymphoma, which is associated with serious toxicities including hypersensitivity, pancreatitis and thrombosis. Methods: To evaluate the toxicity of L-ASP in real clinical settings, we included the patients with L-ASP adverse drug reactions (ADRs) reported in a regional pharmacovigilance center of Seoul St. Mary’s hospital from January 2014 to December 2015. Results: A total of 83 cases of L-ASP related ADRs were reported in 54 patients. Of these 83 cases, 65 cases (78.3%, 65/83) were spontaneously reported and 18 cases (21.7%, 18/83) were detected by further medical records review. Of the patients with ADRs, pediatric patients accounted for 83.3% of the cases (45/54) and median age was 9 years. The most common clinical manifestations of ADRs were hematology manifestations (31.3%, 26/83), followed by hepatobiliary manifestations (18.1%, 15/ 83). Thirty-four serious ADRs were reported in 19 patients. The sserious ADR group showed significantly longer hospitalization and higher rate of discontinuation of L-ASP than the non-serious ADR group (p = 0.005, 0.03). The most common clinical manifestations of serious ADRs were hepatobiliary manifestations (41.2%, 14/34). In total, 8 cases (9.6%, 8/ 83) of unlabeled ADRs were identified. They were serious ADRs. Conclusion: We identified unlabeled serious ADRs of L-ASP. Also, correlations were observed between serious ADRs and length of hospitalization, discontinuation rate respectively. Further investigations and developed spontaneous ADR reporting systems are needed to evaluate these correlations.

목차

ABSTRACT
 연구 방법
  연구 기간 및 연구 대상
  자료 수집 및 분석
  통계 분석 방법
 연구 결과
  약물 유해반응 보고 건수 및 대상환자 특성
  약물투여와 유해반응 인과관계 평가
  약물 유해반응 분류
  INR 상승군과 비 상승군 분류
  중대한 유해반응
  국내 허가사항 미 반영 유해반응
 고찰 및 결론
 참고문헌

저자

  • 고경미 [ Kyung Mi Ko | 가톨릭 대학교 기초임상약리학 교실 ]
  • 나현오 [ Hyen O La | 가톨릭 대학교 약학대학 ] Corresponding author

참고문헌

자료제공 : 네이버학술정보

간행물 정보

발행기관

  • 발행기관명
    한국임상약학회 [Korean College of Clinical Pharmacy]
  • 설립연도
    1
  • 분야
    의약학>약학
  • 소개
    합리적 약물치료(rational pharmacotherapy)의 보장 및 증진을 궁극목적으로 하며 이를 달성하기 위해 임상약학의 발전과 회원 상호간의 친목을 도모한다.

간행물

  • 간행물명
    한국임상약학회지 [Korean Journal of Clinical Pharmacy]
  • 간기
    계간
  • pISSN
    1226-6051
  • 수록기간
    1991~2026
  • 등재여부
    KCI 등재
  • 십진분류
    KDC 518 DDC 615

이 권호 내 다른 논문 / 한국임상약학회지 제27권 제3호

    피인용수 : 0(자료제공 : 네이버학술정보)

    함께 이용한 논문 이 논문을 다운로드한 분들이 이용한 다른 논문입니다.

      페이지 저장